• OncoSpan range expanded to include FFPE and cfDNA formats to mimic solid tumors and liquid biopsy samples, respectively
• Cell-line derived reference standards offer an unlimited and reproducible resource to help ensure consistency during diagnostic assay workflows
The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. Eisai join AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the bio-incubator programme
• Special licensing terms enable rapid access to CHOSOURCE platform to streamline SARS-CoV-2 therapeutic development and production processes
• Supports global efforts to develop therapeutics, diagnostic assay components and vaccines to combat the COVID-19 Coronavirus pandemic
Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.
By Annie Zeng
Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of its first peer-reviewed paper. The open access paper, published in the American Journal of Respiratory and Critical Care Medicine1, describes TMEM16A potentiation via ETX001 as a novel approach for the treatment of cystic fibrosis (CF).
Experts addressed different possible models for optimising data collection to support the adoption of cell and gene therapies in the UK. Barriers to digital integration, post-launch data collection and outcomes-based reimbursement were the primary focus of the day.